Levaquin is produced and marketed by Janssen Pharmaceuticals Inc., a Johnson & Johnson company.
The FDA has also approved Levaquin to lower the chances of contracting the plague after exposure to Yersinia pestis.
Yersinia pestis and plagues in human historyYersinia pestis, previously known as Pasteurella pestis, is a bacterium which can infect humans and many animals.
Infection can take three forms:
- the infamous bubonic plagues
Yersinia pestis and the terrorist threatScientists today fear that Yersinia pestis could be used in terrorist attacks. In fact, the Centers for Disease Control and Prevention (CDC), USA, classifies Yersinia pestis as a Category A pathogen, and says preparations should be made for possible terrorist attacks.
Yersinia pestis very rare todayDespite its devastating history, the bacterium is extremely rare today. According to WHO (World Health Organization), there are approximately 1,000 to 2,000 reported cases of human infection annually worldwide.
Testing Levaquin's efficacy in preventing and treating Yersinia pestis exposure was done on African Green monkeys. For ethical reasons, human trials were not possible.
The following drugs are now FDA approved for the treatment and/or prevention of plague:
- Levaquin (levofloxacin)
Written by Christian Nordqvist